DR Joris Hemelaar
|Tel||+44 (0)1865 221021|
I obtained my BSc and MSc (cum laude) in Molecular Biology and Genetics at Leiden University, The Netherlands (1997). I went on to complete a DPhil in Molecular Immunology with Prof Sir Andrew McMichael FRS at the Weatherall Institute of Molecular Medicine and Trinity College, University of Oxford (2001). This was followed by post-doctoral research with Prof Hidde Ploegh at the Harvard Medical School.
I went on to complete my BM BCh medical degree at Magdalen College, Oxford (2007) and, after working as a Foundation Doctor in London for two years, I returned to Oxford in 2009 to commence my Specialty Training in Obstetrics and Gynaecology as an Academic Clinical Fellow at the John Radcliffe Hospital.
In 2012 I was appointed as a Clinical Lecturer in the Nuffield Department of Obstetrics & Gynaecology, and recently I was awarded the Sir Paul Nurse Junior Research Fellowship at Linacre College, Oxford.
SELECTED FELLOWSHIPS AND AWARDS
- 2014 Award for most highly cited article in AIDS journal
- 2013 Membership of the Royal College of Obstetricians and Gynaecologists, London.
- 2012 Diploma in Evidence-Based Medicine, University of Oxford
- 2009 - 2012 Academic Clinical Fellowship (NIHR)
- 2005 - 2007 Foulkes Foundation Fellowship.
- 1998 - 2001 Medical Research Council PhD Fellowship.
- 1997 Talent Scholarship, Minister of Education, The Netherlands.
BM BCh BSc(Hons) MSc PGDip DPhil MRCOG
- Sir Paul Nurse Junior Research Fellow, Linacre College, Oxford.
- Specialty Registrar, Obstetrics & Gynaecology, John Radcliffe Hospital, Oxford.
- Senior Researcher, Wits University, South Africa.
- Consultant, HIV Vaccine Initiative, WHO/UNAIDS, Geneva.
Maternal HIV infection and adverse pregnancy outcomes.
Maternal HIV infection not only poses a risk of transmission of HIV to the baby, but is also associated with increased rates of adverse pregnancy outcomes, such as low birth weight (LBW), preterm birth (PTB), intrauterine growth restriction (IUGR), and stillbirth (SB). The HIV pandemic continues to grow, with 35 million people currently infected. 92 percent of HIV-infected pregnant women live in sub-Saharan Africa. Preterm birth and low birth weight are the leading causes of perinatal morbidity and mortality around the world. Our aims are to accurately estimate the burden of adverse pregnancy outcomes associated with maternal HIV infection and antiretroviral treatment, and to elucidate the mechanisms underlying these pathologies with a view to developing targeted, preventative and interventional strategies.
To investigate the associations of maternal HIV infection and antiretroviral treatment with a range of adverse pregnancy outcomes we are conducting a number of systematic literature reviews and meta-analyses. We are also conducting a large-scale prospective pregnancy cohort study in Chris Hani Baragwanath Hospital, Soweto, South Africa, located in an area with a very high HIV prevalence (30%). We closely follow HIV-positive and HIV-negative women throughout pregnancy, which will give us a better understanding of the relationship between maternal HIV infection, antiretroviral therapy and adverse pregnancy outcomes. Within the same cohort, and as an adjunct to INTERBIO-21st, we collect biological samples (blood and placenta) which we use to characterise the immune responses associated with HIV infection in pregnancy by which HIV may cause PTB and IUGR. A better understanding of these mechanisms should pave the way to the development of specific preventative and therapeutic strategies applicable in the developing world.
Global molecular epidemiology of HIV.
HIV-1 genetic variability within individuals and populations plays a central role in the HIV pandemic. Multiple zoonotic transmissions of SIV to humans have resulted in distinct HIV lineages in humans which have further diversified within the population over time. High rates of mutation and recombination during HIV reverse transcription create a genetic diversity in the host which is subject to selection pressures by the immune response and antiretroviral treatment. As a result, the global distribution of HIV-1 subtypes and recombinants is extremely complex and dynamic. The increasing diversity has profound implications for many aspects of the pandemic, including viral pathogenicity, transmission, diagnosis, treatment, and vaccine development. HIV-1 genetic diversity surveillance is therefore crucial in tackling the pandemic and in collaboration with the HIV Vaccine Initiative at the World Health Organisation, Geneva, we collect HIV molecular epidemiology data from around the world. We use this data to describe the distribution and trends in national, regional, and global HIV genetic diversity, information which is essential for HIV vaccine development. We further link our HIV distribution data to regional and global transport and accessibility models to investigate the role of infrastructure and human migration in the spread of HIV.
The origin and diversity of the HIV-1 pandemic.
Hemelaar J., (2012), Trends Mol Med, 18, 182 - 192
Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis.
Wedi CO. et al, (2016), Lancet HIV, 3, e33 - e48
Management and outcomes of pregnancies among women with HIV in Oxford, UK, in 2008-2012.
Montgomery-Taylor S. and Hemelaar J., (2015)
Management and outcomes of pregnancies among women with HIV in Oxford, UK, in 2008-2012
Montgomery-Taylor S. and Hemelaar J., (2015), International Journal of Gynecology and Obstetrics, 130, 59 - 63
The Impact of an ECV Service is Limited by Antenatal Breech Detection: A Retrospective Cohort Study.
Hemelaar J. et al, (2015), Birth, 42, 165 - 172
Implications of HIV diversity for the HIV-1 pandemic
Hemelaar J., (2013), Journal of Infection, 66, 391 - 400
- Dr Chrystelle Wedi (DPhil Student, Rhodes Scholar)
- Dr Christian Bwangandu (PhD Student, South Africa)
- Richard Longwango (Laboratory Technician, South Africa)
- Prof Stephen Kennedy, NDOG, Oxford
- Prof Shane Norris, DPHRU, University of the Witwatersrand, South Africa
- Prof Philip Goulder, Peter Medawar Building for Pathogen Research, Oxford
- Dr Ulrich Fruth, WHO, Geneva, Switzerland
- Dr Peter Ghys, UNAIDS, Geneva, Switzerland
- Prof Bette Korber, Los Alamos National Laboratory, USA
- Dr Andy Tatem, University of Southampton, UK